期刊
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
卷 22, 期 5, 页码 310-317出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ijir.2010.21
关键词
erectile dysfunction; type 2 diabetes; sildenafil citrate
资金
- Pfizer Pharmaceuticals Limited [PRC-IZ-02-002]
The aims of this study were to investigate the prevalence of ED in Chinese men with type 2 diabetes mellitus, and evaluate the efficacy and safety of sildenafil citrate in these patients. Patients from 42 outpatient diabetes clinics with type 2 diabetes mellitus and ED as defined by the International Index of Erectile Function (IIEF)-5 were studied. Participants with ED received three doses (100 mg each) of sildenafil citrate for use over 3 months. Efficacy of sildenafil citrate was assessed using the IIEF-5 and the Global Efficacy Questionnaire (GEQ). Adverse events were recorded by patients in a daily diary. A total of 5477 participants were evaluated, and 75.2% had ED. Age, duration of diabetes and glycosylated hemoglobin (HbA(1)c) > 6.5% were independently and significantly associated with the presence and degree of ED. Patients who received pharmacotherapy (N = 389) reported significant improvements. The rate of erections as determined by the GEQ was also significantly improved following treatment. ED is a common complication in Chinese men with type 2 diabetes mellitus, and certain risk factors are associated with the presence of ED and severity. Sildenafil citrate is a safe and effective treatment for these patients. International Journal of Impotence Research (2010) 22, 310-317; doi: 10.1038/ijir.2010.21; published online 2 September 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据